$0.011 -0.0 -72.5%
Last Trade - 26/02/21
| Market Cap | £77.2k |
| Enterprise Value | £4.64m |
| Revenue | £1.08m |
| Position in Universe | th / 6715 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009E | 2010E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.29 | 0.50 | 0.57 | 0.59 | 0.99 | 1.37 | +36.2% | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
ReGen Biologics, Inc. (ReGen) is a development stage orthopedic products company that develops, manufactures and markets tissue growth and repair products for United States and global markets. The Company's collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. Some of these applications are marketable while others are in various stages of development. ReGen’s first approved product using its collagen matrix technology is the Menaflex collagen meniscus implant device (also known as the CMI), which is marketed for sale in the European Union (EU), Switzerland, Turkey, and the Republic of South Africa, through the Company’s subsidiary, ReGen Biologics AG.
| Last Annual | December 31st, 2008 |
| Last Interim | June 30th, 2009 |
| Incorporated | September 1, 1987 |
| Public Since | June 28, 1996 |
| No. of Shareholders: | 234 |
| No. of Employees: | 16 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | |
| Exchange | Pink Sheets on Nasdaq |
| Shares in Issue | 13,151,152 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 411 Hackensack Ave Fl 10, HACKENSACK, 07601-6326, United States |
| Web | http://www.ivysportsmed.com/ |
| Phone | +1 201 6515140 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 26/02/21, shares in Regen Biologics Inc are trading at $0.011, giving the company a market capitalisation of £77.2k. This share price information is delayed by 15 minutes.
Shares in Regen Biologics Inc are currently trading at $0.011 and the price has moved by 0.450k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Regen Biologics Inc price has moved by 0.320k% over the past year.
There are no analysts currently covering Regen Biologics Inc.
Regen Biologics Inc is scheduled to issue upcoming financial results on the following dates:
Regen Biologics Inc does not currently pay a dividend.
Regen Biologics Inc does not currently pay a dividend.
Regen Biologics Inc does not currently pay a dividend.
To buy shares in Regen Biologics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Regen Biologics Inc are currently trading at $0.011, giving the company a market capitalisation of £77.2k.
Here are the trading details for Regen Biologics Inc:
We were not able to load our ranking data for Regen Biologics Inc
We were not able to load any forecast data for Regen Biologics Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Regen Biologics Inc. Over the past six months, the relative strength of its shares against the market has been 72.98%. At the current price of $0.011, shares in Regen Biologics Inc are trading at 6.48% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Regen Biologics Inc.
Regen Biologics Inc's management team is headed by:
Here are the top five shareholders of Regen Biologics Inc based on the size of their shareholding:
